| 产品名称 | Tivozanib - AV 951 | KRN 951 |
| 产品货号 | Axon 1717 CAS [475108-18-0] MF C22H19ClN4O5MW 454.86 Purity: 98% Moderately soluble in DMSO Description A highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGFR1, 2 and 3, c-KIT and PDGFR (IC50: 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively) References Certificates Categories Extra info K Nakamura et al. KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties. Cancer Res. 2006, 66(18), 9134-9142. Eri Taguchi et al. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci. 2008, 99(3), 623. C Campas et al. Tivozanib. Drugs Fut. 2009, 34(10), 793. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology VEGFR RTK class IV; EC 2.7.10.1 VEGFR1, 2, and 3 tyrosine kinase inhibitor Chemical name 1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea Parent CAS No. [475108-18-0] Order Size Unit Price Stock 5 mg €99.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
Tivozanib - AV 951 | KRN 951Axon 1717 CAS [475108-18-0] MF C22H19ClN4O5
Description
A highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGFR1, 2 and 3, c-KIT and PDGFR (IC50: 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively)
VEGFR1, 2, and 3 tyrosine kinase inhibitor
Chemical name1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea Parent CAS No.[475108-18-0] |
| 产品资料 |
